{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:01:14Z","timestamp":1793721674896,"version":"4.6.1"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE:<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of 0.1% cyclosporine A cationic emulsion (CsA CE) following prior treatment with 0.05% cyclosporine A anionic emulsion (CsA AE) in moderate to severe dry eye disease (DED).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS:<\/jats:title>\n                    <jats:p>We retrospectively identified patients with moderate-to-severe DED who had shown an inadequate response to twice-daily use of topical 0.05% CsA AE but showed a significant improvement after switching to 0.1% CsA CE daily. Dry eye parameters before and after CsA CE were evaluated by tear break-up time (TBUT), corneal fluorescein staining (CFS), cornea sensitivity, Schirmer's test without anesthetics, and Ocular Surface Disease Index questionnaire.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Twenty-three patients, including ten patients with Sjogren syndrome and five patients with rheumatoid arthritis, were reviewed. After a 2-month course of treatment with topical 0.1% CsA CE, significant improvements were noted for CFS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), corneal sensitivity (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.008), and TBUT (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.01). Efficacy was similar in the autoimmune versus nonautoimmune group. 39.1% of patients reported treatment-related adverse events, while the majority was transient instillation pain. Visual acuity and intraocular pressure had no significant changes during the study.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>In patients with moderate to severe DED refractory to 0.05% cyclosporine, shifting to 0.1% cyclosporine showed improvement in objective signs but with lower treatment tolerability in the short term.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/tjo.tjo-d-22-00140","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T04:57:11Z","timestamp":1678683431000},"page":"68-74","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy and safety of topical cyclosporine 0.1% in moderate-to-severe dry eye disease refractory to topical cyclosporine 0.05% regimen"],"prefix":"10.4103","volume":"13","author":[{"given":"Yuan-Hsi","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20240830","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II epidemiology report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul Surf"},{"key":"R2-11-20240830","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ajo.2017.06.033","article-title":"Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older","volume":"182","author":"Farrand","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"R3-11-20240830","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0181-5512(07)89584-2","article-title":"A new approach for better comprehension of diseases of the ocular surface","volume":"30","author":"Baudouin","year":"2007","journal-title":"J Fr Ophtalmol"},{"key":"R4-11-20240830","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II definition and classification report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"key":"R5-11-20240830","first-page":"192","article-title":"Dry eye syndrome","volume":"6","author":"Javadi","year":"2011","journal-title":"J Ophthalmic Vis Res"},{"key":"R6-11-20240830","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/00003226-199705000-00005","article-title":"Topical cyclosporin A in the management of postkeratoplasty glaucoma","volume":"16","author":"Perry","year":"1997","journal-title":"Cornea"},{"key":"R7-11-20240830","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.ophtha.2005.05.013","article-title":"Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years","volume":"112","author":"Barber","year":"2005","journal-title":"Ophthalmology"},{"key":"R9-11-20240830","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejpb.2017.03.006","article-title":"Cyclosporine a delivery to the eye: A comprehensive review of academic and industrial efforts","volume":"117","author":"Lallemand","year":"2017","journal-title":"Eur J Pharm Biopharm"},{"key":"R10-11-20240830","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/14656566.2018.1479742","article-title":"Evaluating the novel application of cyclosporine 0.1% in ocular surface disease","volume":"19","author":"Boboridis","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"R11-11-20240830","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/ICO.0b013e31825e83f4","article-title":"Distribution of cyclosporine a in ocular tissues after topical administration of cyclosporine a cationic emulsions to pigmented rabbits","volume":"32","author":"Daull","year":"2013","journal-title":"Cornea"},{"key":"R12-11-20240830","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jfo.2014.05.001","article-title":"Ocular tolerability and efficacy of a cationic emulsion in patients with mild to moderate dry eye disease \u2013 A randomised comparative study","volume":"37","author":"Amrane","year":"2014","journal-title":"J Fr Ophtalmol"},{"key":"R13-11-20240830","doi-asserted-by":"crossref","first-page":"520","DOI":"10.5301\/ejo.5000952","article-title":"A randomized study of the efficacy and safety of 0.1% cyclosporine a cationic emulsion in treatment of moderate to severe dry eye","volume":"27","author":"Baudouin","year":"2017","journal-title":"Eur J Ophthalmol"},{"key":"R14-11-20240830","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5301\/ejo.5000779","article-title":"Efficacy and safety of 0.1% cyclosporine a cationic emulsion in the treatment of severe dry eye disease: A multicenter randomized trial","volume":"26","author":"Leonardi","year":"2016","journal-title":"Eur J Ophthalmol"},{"key":"R15-11-20240830","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/bjophthalmol-2017-311801","article-title":"Efficacy and safety of 0.1% ciclosporin a cationic emulsion in dry eye disease: A pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies","volume":"103","author":"Leonardi","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"R16-11-20240830","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2147\/OPTH.S150957","article-title":"Topical ocular 0.1% cyclosporine a cationic emulsion in dry eye disease patients with severe keratitis: Experience through the French early-access program","volume":"12","author":"Pisella","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"R18-11-20240830","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/00003226-200310000-00008","article-title":"Grading of corneal and conjunctival staining in the context of other dry eye tests","volume":"22","author":"Bron","year":"2003","journal-title":"Cornea"},{"key":"R19-11-20240830","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/ICO.0000000000002244","article-title":"Protective effects of cyclosporine a emulsion versus cyclosporine a cationic emulsion against desiccation stress in human corneal epithelial cells","volume":"39","author":"Hwang","year":"2020","journal-title":"Cornea"},{"key":"R20-11-20240830","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0161-6420(00)00035-X","article-title":"Efficacy and safety of cyclosporin a ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: A dose-ranging, randomized trial. The cyclosporin a phase 2 study group","volume":"107","author":"Stevenson","year":"2000","journal-title":"Ophthalmology"},{"key":"R21-11-20240830","first-page":"CD010051","article-title":"Topical cyclosporine a therapy for dry eye syndrome","volume":"9","author":"de Paiva","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"R22-11-20240830","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1089\/jop.2020.0011","article-title":"Cationic emulsion-based artificial tears as a mimic of functional healthy tear film for restoration of ocular surface homeostasis in dry eye disease","volume":"36","author":"Daull","year":"2020","journal-title":"J Ocul Pharmacol Ther"},{"key":"R23-11-20240830","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.clinthera.2018.09.012","article-title":"Persistence of efficacy of 0.1% cyclosporin a cationic emulsion in subjects with severe keratitis due to dry eye disease: A nonrandomized, open-label extension of the SANSIKA study","volume":"40","author":"Labetoulle","year":"2018","journal-title":"Clin Ther"},{"key":"R24-11-20240830","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jtos.2013.10.002","article-title":"Challenges in using signs and symptoms to evaluate new biomarkers of dry eye disease","volume":"12","author":"Sullivan","year":"2014","journal-title":"Ocul Surf"},{"key":"R25-11-20240830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/5140823","article-title":"Neuronal changes in the diabetic cornea: Perspectives for neuroprotection","volume":"2016","author":"Bikbova","year":"2016","journal-title":"Biomed Res Int"},{"key":"R26-11-20240830","doi-asserted-by":"crossref","first-page":"100762","DOI":"10.1016\/j.preteyeres.2019.05.003","article-title":"Corneal nerves in health and disease","volume":"73","author":"Al-Aqaba","year":"2019","journal-title":"Prog Retin Eye Res"},{"key":"R27-11-20240830","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtos.2017.05.002","article-title":"TFOS DEWS II pain and sensation report","volume":"15","author":"Belmonte","year":"2017","journal-title":"Ocul Surf"},{"key":"R28-11-20240830","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1167\/iovs.06-1129","article-title":"The cornea in Sjogren's syndrome: An in vivo confocal study","volume":"48","author":"Villani","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R29-11-20240830","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1167\/iovs.13-12370","article-title":"Corneal nerve structure and function in patients with Non-Sjogren dry eye: Clinical correlations","volume":"54","author":"Labb\u00e9","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R30-11-20240830","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/ICO.0b013e3181acf68d","article-title":"Corneal and conjunctival sensitivity in patients with dry eye: The effect of topical cyclosporine therapy","volume":"29","author":"Toker","year":"2010","journal-title":"Cornea"},{"key":"R31-11-20240830","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nm0497-421","article-title":"Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin a","volume":"3","author":"Steiner","year":"1997","journal-title":"Nat Med"},{"key":"R32-11-20240830","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/ICO.0b013e3182281028","article-title":"Cyclosporine a induces nerve growth factor expression via activation of MAPK p38 and NFAT5","volume":"30","author":"Lee","year":"2011","journal-title":"Cornea"},{"key":"R33-11-20240830","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/ceo.12898","article-title":"Increased corneal sub-basal nerve density in patients with Sj\u00f6gren syndrome treated with topical cyclosporine A","volume":"45","author":"Levy","year":"2017","journal-title":"Clin Exp Ophthalmol"},{"key":"R34-11-20240830","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2147\/OPTH.S89700","article-title":"Associations between signs and symptoms of dry eye disease: A systematic review","volume":"9","author":"Bartlett","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"R35-11-20240830","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/01.ico.0000133997.07144.9e","article-title":"The lack of association between signs and symptoms in patients with dry eye disease","volume":"23","author":"Nichols","year":"2004","journal-title":"Cornea"},{"key":"R36-11-20240830","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S0161-6420(97)30125-0","article-title":"Relation between signs and symptoms of dry eye in the elderly. A population-based perspective","volume":"104","author":"Schein","year":"1997","journal-title":"Ophthalmology"},{"key":"R37-11-20240830","first-page":"280","article-title":"A 0,05% cyclosporine treatment of the advanced dry eye syndrome","volume":"107","author":"Kujawa","year":"2005","journal-title":"Klin Oczna"},{"key":"R38-11-20240830","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.clae.2017.09.015","article-title":"The effect of ageing on the ocular surface parameters","volume":"41","author":"Rico-Del-Viejo","year":"2018","journal-title":"Cont Lens Anterior Eye"},{"key":"R39-11-20240830","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41433-018-0289-7","article-title":"Real-world experience at a Scottish University teaching hospital regarding the tolerability and persistence with topical Ciclosporin 0.1% (Ikervis) treatment in patients with dry eye disease","volume":"33","author":"Hind","year":"2019","journal-title":"Eye (Lond"}],"container-title":["Taiwan Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.TJO-D-22-00140","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:09:33Z","timestamp":1787166573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.TJO-D-22-00140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/tjo.tjo-d-22-00140","relation":{},"ISSN":["2211-5056"],"issn-type":[{"value":"2211-5056","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}